Director & 10% Owner Panacea Sells $3.16M in Atara Biotherapeutics Shares
ATRA has more than doubled off its 52-week low of $3.92.
Summary
A director and 10% owner, Panacea Venture, sold over $3.16 million worth of Atara Biotherapeutics shares, reducing their beneficial ownership to 16.1%.
Key Events · Ownership and Investor Activity · ATRA
-
Significant Share Sale
Panacea Venture Healthcare Fund II, L.P. sold 313,446 shares of Common Stock in open market transactions at a weighted average price of $10.0975 per share, totaling approximately $3.16 million.
-
Director & 10% Owner Disposition
The sale was made by entities associated with James Huang, a director and beneficial owner, reducing the Panacea group's aggregate beneficial ownership to 16.1% of outstanding shares.
-
Follows Delisting Notice
This significant disposition occurs shortly after Atara Biotherapeutics received a Nasdaq delisting notice on May 1, 2026, due to failing to meet minimum market value requirements.
-
Concurrent Form 4 Filing
This transaction was also reported in a Form 4 filing on May 11, 2026, confirming the sale by a director and 10% owner.
Analysis · ATRA · Life Sciences
Panacea Venture, a significant beneficial owner and associated with a director, sold a substantial block of Atara Biotherapeutics shares. This sale, valued at over $3.16 million, represents a notable reduction in their stake, occurring shortly after the company received a Nasdaq delisting notice and amidst ongoing efforts to address regulatory challenges. This transaction, also reported in a concurrent Form 4, indicates a significant disposition by a key investor.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRA was trading at $9.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.